Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 343

Sort by

Sort Order Select

Journal Articles

Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population

Blood (2023) 141 (20): 2493–2507.

https://doi.org/10.1182/blood.2022018248

Published: 2023

Includes: Supplemental data

Journal Articles

Long-Term Outcomes of High-Risk Stage 1/2 Classic Hodgkin Lymphoma Managed with an Advanced Stage Treatment Approach

Jowon Laura Kim, Diego Villa, R. Petter Tonseth, Alina S. Gerrie, Don Wilson, Francois Benard, Christopher P. Venner, Brian Skinnider, Pedro Farinha, Graham W. Slack, Randy D. Gascoyne, David W. Scott, Joseph M. Connors, Laurie H. Sehn, Kerry J. Savage

Blood (2022) 140 (Supplement 1): 9437–9438.

https://doi.org/10.1182/blood-2022-162199

Published: 2022

Journal Articles

A gene expression–based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma

Rebecca L. Johnston, Anja Mottok, Fong Chun Chan, Aixiang Jiang, Arjan Diepstra, Lydia Visser, Adèle Telenius, Randy D. Gascoyne, Debra L. Friedman, Cindy L. Schwartz, Kara M. Kelly, David W. Scott, Terzah M. Horton, Christian Steidl

Blood (2022) 139 (6): 889–893.

https://doi.org/10.1182/blood.2021011941

Published: 2022

Includes: Supplemental data

Journal Articles

Population-Wide Introduction of Dose-Adjusted EPOCH-R Is Associated with Improved Outcome of High Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements with Diffuse Large B-Cell Lymphoma Morphology

Blood (2021) 138 (Supplement 1): 1458.

https://doi.org/10.1182/blood-2021-145954

Published: 2021

Journal Articles

Characterization of DLBCL with a PMBL gene expression signature

Blood (2021) 138 (2): 136–148.

https://doi.org/10.1182/blood.2020007683

Published: 2021

Includes: Supplemental data

Journal Articles

The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC

Blood (2021) 137 (16): 2196–2208.

https://doi.org/10.1182/blood.2020007193

Published: 2021

Includes: Supplemental data

Journal Articles

Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma

David D. W. Twa, Derrick G. Lee, King L. Tan, Graham W. Slack, Susana Ben-Neriah, Diego Villa, Joseph M. Connors, Laurie H. Sehn, Anja Mottok, Randy D. Gascoyne, David W. Scott, Christian Steidl, Kerry J. Savage

Blood (2021) 137 (9): 1256–1259.

https://doi.org/10.1182/blood.2020006338

Published: 2021

Includes: Supplemental data

Journal Articles

The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141168

Published: 2020

Journal Articles

Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing

Blood (2020) 136 (5): 572–584.

https://doi.org/10.1182/blood.2019002385

Published: 2020

Includes: Supplemental data

Journal Articles

Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R 2 -CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study

Blood (2019) 134 (Supplement_1): 3475.

https://doi.org/10.1182/blood-2019-123948

Published: 2019

Journal Articles

Mutations Affecting RNA Binding Proteins Are a Novel Feature of Mantle Cell Lymphoma

Blood (2019) 134 (Supplement_1): 1478.

https://doi.org/10.1182/blood-2019-129136

Published: 2019

Journal Articles

Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies

Blood (2019) 134 (Supplement_1): 4092.

https://doi.org/10.1182/blood-2019-123083

Published: 2019

Journal Articles

TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP

Pedro Farinha, MD PhD, Daisuke Ennishi, MD PhD, Anja Mottok, MD PhD, Susana Ben-Neriah, BSc, Barbara Meissner, PhD, Merrill Boyle, BSc, Jeffrey W. Craig, MD PhD, Graham W Slack, MD, Diego Villa, MD MPH, Kerry J Savage, BSc, MD MSc, Laurie H Sehn, MD, Ryan D. Morin, PhD, Marco A. Marra, PhD, Joseph M. Connors, MD, Randy D. Gascoyne, MD, Christian Steidl, MD, David W. Scott, MBChB, PhD

Blood (2019) 134 (Supplement_1): 3964.

https://doi.org/10.1182/blood-2019-121943

Published: 2019

Journal Articles

Molecular Correlates of Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma

Robert Kridel, MDMPH,PhD, Keren Isaev, MSc, Daisuke Ennishi, MD PhD, Brian Skinnider, MD, Karen Mungall, PhD, Andrew J. Mungall, PhD, Mehran Bakhtiari, MSc, Rosemarie Tremblay-Lemay, MD MSc, FRCPC, Barbara Meissner, PhD, Susana Ben-Neriah, BSc, Merrill Boyle, BSc, Diego Villa, MD MPH, Marco A. Marra, PhD, Christian Steidl, MD, Randy D. Gascoyne, MD, Kerry J Savage, BSc, MD MSc, David W. Scott, MBChB, PhD

Blood (2019) 134 (Supplement_1): 2763.

https://doi.org/10.1182/blood-2019-124235

Published: 2019

Journal Articles

Diffuse Large B-Cell Lymphomas with a Molecular PMBCL Expression Signature Represent a Distinct Molecular Subtype Associated with Poor Clinical Outcome

Gerben Duns, PhD, Elena Viganò, PhD, Daisuke Ennishi, MD PhD, Clementine Sarkozy, MD, Stacy Hung, Elizabeth Chavez, Katsuyoshi Takata, MD PhD, Anja Mottok, MD PhD, Randy D. Gascoyne, MD, Ryan D. Morin, PhD, Kerry J Savage, BSc, MD MSc, David W. Scott, MBChB, PhD, Christian Steidl, MD

Blood (2019) 134 (Supplement_1): 922.

https://doi.org/10.1182/blood-2019-131450

Published: 2019

Journal Articles

The whole-genome landscape of Burkitt lymphoma subtypes

Blood (2019) 134 (19): 1598–1607.

https://doi.org/10.1182/blood.2019001880

Published: 2019

Includes: Supplemental data

Journal Articles

Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma

Blood (2019) 134 (10): 802–813.

https://doi.org/10.1182/blood.2019001126

Published: 2019

Includes: Supplemental data

Journal Articles

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma

Blood (2019) 133 (15): 1664–1676.

https://doi.org/10.1182/blood-2018-09-872549

Published: 2019

Includes: Supplemental data

Journal Articles

Molecular Features of Primary Central Nervous System Lymphoma in a Large Tissue Microarray

Diego Villa, MD, Graham W Slack, MD PhD, Muntadhar Al-Moosawi, MD, Susana Ben-Neriah, BSc, Tamara Shenkier, MD, Joseph M. Connors, MD, Laurie H Sehn, MDMPH, Kerry J Savage, BSc, MD MSc, David W. Scott, PhDMD,FRACP,FRCPA, Christian Steidl, MD, Randy D. Gascoyne, MD, King Tan, MD

Blood (2018) 132 (Supplement 1): 348.

https://doi.org/10.1182/blood-2018-99-114218

Published: 2018

Journal Articles

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Francesco d'Amore, MD, Sirpa Leppä, MD, Maria Gomes da Silva, MD PhD, Thomas Relander, Grete Fossum Lauritzsen, Peter De Nully Brown, Antonio Pezzutto, Jeanette K. Doorduijn, MD PhD, Eckhart Weidmann, Michel van Gelder, Achiel Van Hoof, Ilse Christiansen, Unn Merete Fagerli, MD PhD, Hans Hagberg, MD, P.J. Lugtenburg, Jan Walewski, Ka Lung Wu, Hilde Maria Demuynck, Rob Fijnheer, Jacob H. Christensen, Milada Jankovská, MD, Pär L. Josefsson, Hanneke Kluin-Nelemans, Jose Mario Mariz, MD, Mats A. Merup, Thomas Noesslinger, Eric Van Den Neste, Josée M Zijlstra, MD, Georg Hopfinger, MD, VIT Prochazka, MD, Esa Jantunen, MD PhD, Ludmila Boudova, Jose Cabecadas, Andreas Chott, Jan M.A. Delabie, MD PhD, Laurence de Leval, MD, Arjan Diepstra, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Peter Noergaard, Andreas Rosenwald, Grzegorz Rymkiewicz, Christer Sundström, Lorenz Truemper, MD, Gerald Wulf, MD, Lauren Chong, MSc, Alyssa Bouska, PhD, Lynette Smith, Christian Gisselbrecht, Marita Ziepert, PhD, Markus Loeffler, MD, Knut Liestol, Christian Steidl, MD, Randy D. Gascoyne, MD, David W. Scott, PhDMD,FRACP,FRCPA, Bettina Altmann, PhD, Javeed Iqbal, §, Wing C Chan, MD, Helle Toldbod, MS,PhD

Blood (2018) 132 (Supplement 1): 998.

https://doi.org/10.1182/blood-2018-99-110429

Published: 2018

NARROW

Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population

Long-Term Outcomes of High-Risk Stage 1/2 Classic Hodgkin Lymphoma Managed with an Advanced Stage Treatment Approach

A gene expression–based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma

Population-Wide Introduction of Dose-Adjusted EPOCH-R Is Associated with Improved Outcome of High Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements with Diffuse Large B-Cell Lymphoma Morphology

Characterization of DLBCL with a PMBL gene expression signature

The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC

Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma

The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma

Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing

Mutations Affecting RNA Binding Proteins Are a Novel Feature of Mantle Cell Lymphoma

Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies

TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP

Molecular Correlates of Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphomas with a Molecular PMBCL Expression Signature Represent a Distinct Molecular Subtype Associated with Poor Clinical Outcome

The whole-genome landscape of Burkitt lymphoma subtypes

Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma

Molecular Features of Primary Central Nervous System Lymphoma in a Large Tissue Microarray

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only